As of May 27
| +0.18 / +2.24%|
The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 8.50, with a high estimate of 11.00 and a low estimate of 5.00. The median estimate represents a +3.53% increase from the last price of 8.21.
The current consensus among 8 polled investment analysts is to Buy stock in ARIAD Pharmaceuticals Inc. This rating has held steady since May, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.